SEATTLE and BRISBANE, Australia, July 20, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for patients suspected of sepsis, announced today the adoption of SeptiCyte® RAPID by FirstHealth of the Carolinas, a non-profit health system licensed for four hospitals in Pinehurst, Troy, Rockingham and Raeford, North Carolina. SeptiCyte RAPID will be available at FirstHealth as a tool in differentiating…Read More
In Clinical Lab Products, Silvia Cermelli, PhD, and Prashant Wani, PhD say “The delay in sepsis diagnosis not only increases the risk of dying by as much as 8% every hour, but misdiagnosis leads to unnecessary use of strong antibiotic therapies causing health-related burdens on patients and economic burdens on healthcare systems.” Source: Clinical Lab…Read More
Immunexpress, Inc. 25 Jul, 2023, 16:30 ET SeptiCyte® RAPID, an in vitro diagnostic test intended to aid differentiating infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis, demonstrated good analytical performance SEATTLE and BRISBANE, Australia, July 25, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected…Read More
This week we will discuss a new rapid response test for Sepsis with one of the developers, Richard Brandon.
Sepsis describes a syndrome that occurs when severe infection results in critical illness and affects 750,000 Americans annually. Sepsis occurs when a bacterial, viral, or fungal infection causes a significant response from the body’s immune system, causing a high heart rate, fever, or fast breathing. Severe sepsis develops when the infection causes organ damage. Septic shock is the most severe form in which the infection causes low blood pressure, resulting in damage to multiple organs. About three in every 10 patients with severe sepsis, and half of those with septic shock, die in the hospital.
Consider asking the following questions…Read More
From the Slice of Healthcare podcast notes: What you’ll get out of this episode: Richard’s background Overview of Immunexpress The impact of a lack of reliable sepsis diagnostics SeptiCyte technology What’s next?Read More
A sepsis thought leadership article from Richard Brandon PhD, CTO at Immunexpress has just been published in IDTransmission. Sepsis takes a heavy toll on society, causing millions of fatalities worldwide per year and costing upwards of US$50 billion yearly in the US alone. Sepsis can develop from viral, bacterial, and even fungal infections, but bacterial…Read More
From the article Better Health Care Tests, Faster, by Andy Oram, posted on Healthcare IT Today More Accurate Detection of Sepsis Sepsis is one of the most dreaded hospital-spawned conditions: It’s common and can quickly be fatal. According to Dr. Rolland Carlson, CEO of Immunexpress, a sepsis diagnosis often takes 24 hours—far too long for…Read More
Why Better Sepsis Diagnosis Results in Better Outcomes From the CLP article by By Silvia Cermelli, PhD, and Prashant Wani, PhD: Making a Breakthrough in Rapid Sepsis Diagnosis Immunexpress’s SeptiCyte RAPID measures host response to differentiate sepsis from non-infectious systemic inflammation (i.e., SIRS). It is an FDA cleared test for this purpose and has a…Read More
From the article in Infection Control Today SeptiCyte RAPID test Sepsis is an overwhelming immune response to infection that can be life-threatening. Immunexpress’ SeptiCyte RAPID test is meant to ensure the timely and accurate diagnosis of sepsis, which is critical to allow clinicians to rapidly make correct treatment decisions that can improve prognoses and save…Read More